{"id":46801,"date":"2022-08-01T18:01:54","date_gmt":"2022-08-01T16:01:54","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/"},"modified":"2022-08-01T18:01:54","modified_gmt":"2022-08-01T16:01:54","slug":"gc-biopharma-reports-q2-2022-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/","title":{"rendered":"GC Biopharma Reports Q2 2022 Results"},"content":{"rendered":"<div>\n<p>YONGIN, South Korea&#8211;(BUSINESS WIRE)&#8211;GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2022.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/5\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/21\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg\"><\/a><\/p>\n<p>\n<b><span class=\"bwuline\">Second-Quarter Reported Results<\/span><\/b>\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth70\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth33\" colspan=\"1\" rowspan=\"1\" style=\"height:16px;\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Key Figures<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwrowaltcolor1 bwwidth34\" colspan=\"1\" rowspan=\"1\" style=\"height:16px;\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q2 2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwpadl0 bwalignc bwrowaltcolor1 bwwidth33\" colspan=\"1\" rowspan=\"1\" style=\"height:16px;\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Growth<sup>(1)<\/sup><\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth33\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nTotal revenues\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignr bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nKRW 423.2 billion\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth33\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n9.2%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth33\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nOperating Income\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignr bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nKRW 13.1 billion\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth33\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n18.0%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth33\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\nNet Income\n<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwalignr bwwidth34\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\nKRW 10.9 billion\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc bwwidth33\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n45.3%\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<sup>(1)<\/sup> Results and percentages compare to Q2 2021\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b><span class=\"bwuline\">Financial Highlights<\/span><\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nDelivered total revenue growth of 9.2% KRW 423.2 billion (Q2 2021: 387.6 billion), and operating profit increased 18.0% to KRW 13.1 billion (Q2 2021: 11.1 billion) in the second quarter\n<\/li>\n<li>\nUnconsolidated revenues growth of +9.7% driven by strong performance of Vx and Protein businesses international sales\n<\/li>\n<li>\nMaintain double-digit growth in consolidated subsidiaries, including GC Cell(+90.9% YoY) and GC WB(+15.0% YoY), except GC MS(-57.9% YoY)\n<\/li>\n<li>\nInternational Protein and Vx sales growth of 62.4% and 11.2% respectively. In particular, Flu Vx sales recorded the highest performance with improved performance notably in Southern Hemisphere\n<\/li>\n<li>\nContinue to expect strong growth from local\/international business across all segments in second half of the year\n<\/li>\n<li>\nGross profit margin growth of 3.4%p due to product-mix optimization\n<\/li>\n<\/ul>\n<p>\n<b>About GC Biopharma<\/b>\n<\/p>\n<p>\nGC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers globally and has been dedicated to quality healthcare solutions for more than half a century.\n<\/p>\n<p>\n<i>This press release may contain forward-looking statements, which express the current beliefs and expectations of GC Biopharma&#8217;s management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.<\/i>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor\/Media Contact<\/b>\n<\/p>\n<p>\nYelin Jun<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x79;&#101;&#x6c;&#105;&#x6e;&#64;&#x67;c&#x63;o&#x72;p&#x2e;c&#x6f;m\" rel=\"nofollow noopener\" shape=\"rect\">y&#101;&#108;&#x69;&#x6e;&#x40;&#x67;c&#99;&#111;&#114;&#x70;&#x2e;&#x63;om<\/a>\n<\/p>\n<p>\nSohee Kim<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;o&#x3a;&#x73;&#104;&#x6b;&#x69;&#109;2&#x30;&#64;g&#x63;&#x63;&#111;&#x72;&#x70;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#115;&#x68;k&#105;&#x6d;&#50;&#x30;&#64;&#103;&#x63;c&#x6f;&#x72;&#112;&#x2e;c&#111;&#x6d;<\/a>\n<\/p>\n<p>\nHansaem Kim<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;t&#x6f;&#x3a;&#x68;&#115;&#46;k&#x69;&#x6d;&#64;&#103;c&#x63;&#x6f;&#x72;&#112;&#46;c&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x68;&#x73;&#46;k&#x69;&#x6d;&#64;gc&#x63;&#x6f;&#114;p&#x2e;&#x63;&#111;&#109;<\/a>\n<\/p>\n<p>\nHaeun Yoon<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x63;&#x75;&#x74;&#x74;&#x79;&#x39;&#x38;&#48;&#49;&#49;&#55;&#64;&#103;&#99;&#99;&#111;&#114;&#112;&#46;com\" rel=\"nofollow noopener\" shape=\"rect\">&#x63;u&#x74;&#116;y&#x39;&#56;&#x30;&#49;1&#x37;&#64;&#x67;&#99;c&#x6f;&#114;&#x70;&#x2e;c&#x6f;&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>YONGIN, South Korea&#8211;(BUSINESS WIRE)&#8211;GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2022. Second-Quarter Reported Results Key Figures Q2 2022 Growth(1) Total revenues KRW 423.2 billion 9.2% Operating Income KRW 13.1 billion 18.0% Net Income KRW &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46801","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GC Biopharma Reports Q2 2022 Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GC Biopharma Reports Q2 2022 Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"YONGIN, South Korea&#8211;(BUSINESS WIRE)&#8211;GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2022. Second-Quarter Reported Results Key Figures Q2 2022 Growth(1) Total revenues KRW 423.2 billion 9.2% Operating Income KRW 13.1 billion 18.0% Net Income KRW ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-01T16:01:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/21\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"GC Biopharma Reports Q2 2022 Results\",\"datePublished\":\"2022-08-01T16:01:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/\"},\"wordCount\":333,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005312\\\/en\\\/1530233\\\/21\\\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/\",\"name\":\"GC Biopharma Reports Q2 2022 Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005312\\\/en\\\/1530233\\\/21\\\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg\",\"datePublished\":\"2022-08-01T16:01:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005312\\\/en\\\/1530233\\\/21\\\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220801005312\\\/en\\\/1530233\\\/21\\\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/gc-biopharma-reports-q2-2022-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GC Biopharma Reports Q2 2022 Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GC Biopharma Reports Q2 2022 Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/","og_locale":"en_US","og_type":"article","og_title":"GC Biopharma Reports Q2 2022 Results - Pharma Trend","og_description":"YONGIN, South Korea&#8211;(BUSINESS WIRE)&#8211;GC Biopharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 30 June 2022. Second-Quarter Reported Results Key Figures Q2 2022 Growth(1) Total revenues KRW 423.2 billion 9.2% Operating Income KRW 13.1 billion 18.0% Net Income KRW ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/","og_site_name":"Pharma Trend","article_published_time":"2022-08-01T16:01:54+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/21\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"GC Biopharma Reports Q2 2022 Results","datePublished":"2022-08-01T16:01:54+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/"},"wordCount":333,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/21\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/","url":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/","name":"GC Biopharma Reports Q2 2022 Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/21\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg","datePublished":"2022-08-01T16:01:54+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/21\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220801005312\/en\/1530233\/21\/GC%EB%85%B9%EC%8B%AD%EC%9E%90_eng.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/gc-biopharma-reports-q2-2022-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"GC Biopharma Reports Q2 2022 Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46801"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46801\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}